Literature DB >> 22068230

Recent advances in understanding ulcerative colitis.

Antonio Di Sabatino1, Paolo Biancheri, Laura Rovedatti, Thomas Thornton Macdonald, Gino Roberto Corazza.   

Abstract

Ulcerative colitis, one of the two main forms of inflammatory bowel disease, is characterized by inflammation of the large bowel with constant involvement of the rectum, and a possible continuous retrograde distribution up to the cecum. Typical macroscopic lesions are mucosal ulcerations, with immune cell infiltration and cryptic abscesses at histology. Ulcerative colitis usually manifests with bloody diarrhea, is associated with a number of extra-intestinal manifestations, and may be acutely complicated by toxic megacolon. Longstanding disease may predispose to the development of colorectal cancer. Therapeutic options include mesalazine, corticosteroids, immunomodulators and biologic agents; however, if these treatments fail, the only available therapeutic choice remaining is the surgical removal of the colon. This review emphasizes novel concepts in the basic aspects of ulcerative colitis, and, in addition to the current clinical and diagnostic knowledge, it also describes new treatment options for this condition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22068230     DOI: 10.1007/s11739-011-0719-z

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  49 in total

Review 1.  The role of Th1/Th2 polarization in mucosal immunity.

Authors:  Markus F Neurath; Susetta Finotto; Laurie H Glimcher
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

2.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

Review 3.  MMX® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis.

Authors:  Lily P H Yang; Paul L McCormack
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 4.  Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases.

Authors:  Charles N Bernstein; Fergus Shanahan
Journal:  Gut       Date:  2008-05-30       Impact factor: 23.059

5.  Oral contraceptive use and cigarette smoking in Crohn's disease.

Authors:  B Katschinski; D Fingerle; B Scherbaum; H Goebell
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

6.  Epidemiology and natural history of inflammatory bowel diseases.

Authors:  Jacques Cosnes; Corinne Gower-Rousseau; Philippe Seksik; Antoine Cortot
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

7.  Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.

Authors:  Ivan J Fuss; Frank Heller; Monica Boirivant; Francisco Leon; Masaru Yoshida; Stefan Fichtner-Feigl; Zhiqiong Yang; Mark Exley; Atsushi Kitani; Richard S Blumberg; Peter Mannon; Warren Strober
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

8.  Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience.

Authors:  A Oussalah; C Laclotte; J-B Chevaux; M Bensenane; A Babouri; A-A Serre; T Boucekkine; X Roblin; M-A Bigard; L Peyrin-Biroulet
Journal:  Aliment Pharmacol Ther       Date:  2008-07-24       Impact factor: 8.171

9.  Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.

Authors:  Carl A Anderson; Gabrielle Boucher; Charlie W Lees; Andre Franke; Mauro D'Amato; Kent D Taylor; James C Lee; Philippe Goyette; Marcin Imielinski; Anna Latiano; Caroline Lagacé; Regan Scott; Leila Amininejad; Suzannah Bumpstead; Leonard Baidoo; Robert N Baldassano; Murray Barclay; Theodore M Bayless; Stephan Brand; Carsten Büning; Jean-Frédéric Colombel; Lee A Denson; Martine De Vos; Marla Dubinsky; Cathryn Edwards; David Ellinghaus; Rudolf S N Fehrmann; James A B Floyd; Timothy Florin; Denis Franchimont; Lude Franke; Michel Georges; Jürgen Glas; Nicole L Glazer; Stephen L Guthery; Talin Haritunians; Nicholas K Hayward; Jean-Pierre Hugot; Gilles Jobin; Debby Laukens; Ian Lawrance; Marc Lémann; Arie Levine; Cecile Libioulle; Edouard Louis; Dermot P McGovern; Monica Milla; Grant W Montgomery; Katherine I Morley; Craig Mowat; Aylwin Ng; William Newman; Roel A Ophoff; Laura Papi; Orazio Palmieri; Laurent Peyrin-Biroulet; Julián Panés; Anne Phillips; Natalie J Prescott; Deborah D Proctor; Rebecca Roberts; Richard Russell; Paul Rutgeerts; Jeremy Sanderson; Miquel Sans; Philip Schumm; Frank Seibold; Yashoda Sharma; Lisa A Simms; Mark Seielstad; A Hillary Steinhart; Stephan R Targan; Leonard H van den Berg; Morten Vatn; Hein Verspaget; Thomas Walters; Cisca Wijmenga; David C Wilson; Harm-Jan Westra; Ramnik J Xavier; Zhen Z Zhao; Cyriel Y Ponsioen; Vibeke Andersen; Leif Torkvist; Maria Gazouli; Nicholas P Anagnou; Tom H Karlsen; Limas Kupcinskas; Jurgita Sventoraityte; John C Mansfield; Subra Kugathasan; Mark S Silverberg; Jonas Halfvarson; Jerome I Rotter; Christopher G Mathew; Anne M Griffiths; Richard Gearry; Tariq Ahmad; Steven R Brant; Mathias Chamaillard; Jack Satsangi; Judy H Cho; Stefan Schreiber; Mark J Daly; Jeffrey C Barrett; Miles Parkes; Vito Annese; Hakon Hakonarson; Graham Radford-Smith; Richard H Duerr; Séverine Vermeire; Rinse K Weersma; John D Rioux
Journal:  Nat Genet       Date:  2011-02-06       Impact factor: 38.330

10.  Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region.

Authors:  Jeffrey C Barrett; James C Lee; Charles W Lees; Natalie J Prescott; Carl A Anderson; Anne Phillips; Emma Wesley; Kirstie Parnell; Hu Zhang; Hazel Drummond; Elaine R Nimmo; Dunecan Massey; Kasia Blaszczyk; Timothy Elliott; Lynn Cotterill; Helen Dallal; Alan J Lobo; Craig Mowat; Jeremy D Sanderson; Derek P Jewell; William G Newman; Cathryn Edwards; Tariq Ahmad; John C Mansfield; Jack Satsangi; Miles Parkes; Christopher G Mathew; Peter Donnelly; Leena Peltonen; Jenefer M Blackwell; Elvira Bramon; Matthew A Brown; Juan P Casas; Aiden Corvin; Nicholas Craddock; Panos Deloukas; Audrey Duncanson; Janusz Jankowski; Hugh S Markus; Christopher G Mathew; Mark I McCarthy; Colin N A Palmer; Robert Plomin; Anna Rautanen; Stephen J Sawcer; Nilesh Samani; Richard C Trembath; Anath C Viswanathan; Nicholas Wood; Chris C A Spencer; Jeffrey C Barrett; Céline Bellenguez; Daniel Davison; Colin Freeman; Amy Strange; Peter Donnelly; Cordelia Langford; Sarah E Hunt; Sarah Edkins; Rhian Gwilliam; Hannah Blackburn; Suzannah J Bumpstead; Serge Dronov; Matthew Gillman; Emma Gray; Naomi Hammond; Alagurevathi Jayakumar; Owen T McCann; Jennifer Liddle; Marc L Perez; Simon C Potter; Radhi Ravindrarajah; Michelle Ricketts; Matthew Waller; Paul Weston; Sara Widaa; Pamela Whittaker; Panos Deloukas; Leena Peltonen; Christopher G Mathew; Jenefer M Blackwell; Matthew A Brown; Aiden Corvin; Mark I McCarthy; Chris C A Spencer; Antony P Attwood; Jonathan Stephens; Jennifer Sambrook; Willem H Ouwehand; Wendy L McArdle; Susan M Ring; David P Strachan
Journal:  Nat Genet       Date:  2009-11-15       Impact factor: 38.330

View more
  15 in total

1.  Temporal comorbidity of mental disorder and ulcerative colitis.

Authors:  David Cawthorpe; Marta Davidson
Journal:  Perm J       Date:  2015

2.  No association between the SOCS-1 -1478CA/del polymorphism and ulcerative colitis in Turkish subjects.

Authors:  Mustafa Hartavi; Selim Giray Nak; Barbaros Oral; Adem Deligönül
Journal:  Mol Biol Rep       Date:  2014-07-02       Impact factor: 2.316

3.  Iron replacement in inflammatory bowel diseases: an evolving scenario.

Authors:  Fabiana Busti; Giacomo Marchi; Domenico Girelli
Journal:  Intern Emerg Med       Date:  2019-02-05       Impact factor: 3.397

4.  From impending toxic megacolon to multiple organ failure in severe ulcerative colitis.

Authors:  Antonio Di Sabatino; Paolo Giuffrida; Gino Roberto Corazza
Journal:  Intern Emerg Med       Date:  2012-08-26       Impact factor: 3.397

5.  Impending megacolon: small bowel distension as a predictor of toxic megacolon in ulcerative colitis.

Authors:  Akira Hokama; Tetsuya Ohira; Kazuto Kishimoto; Fukunori Kinjo; Jiro Fujita
Journal:  Intern Emerg Med       Date:  2012-07-28       Impact factor: 3.397

6.  Chymase inhibitor TY-51469 in therapy of inflammatory bowel disease.

Authors:  Wei-Xin Liu; Ying Wang; Li-Xuan Sang; Shen Zhang; Ting Wang; Feng Zhou; Shou-Zhi Gu
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

Review 7.  Clinical approach to diarrhea.

Authors:  Roberto Corinaldesi; Vincenzo Stanghellini; Giovanni Barbara; Paola Tomassetti; Roberto De Giorgio
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

Review 8.  Gut microbiota imbalance and chaperoning system malfunction are central to ulcerative colitis pathogenesis and can be counteracted with specifically designed probiotics: a working hypothesis.

Authors:  Maurizio Bellavia; Giovanni Tomasello; Marcello Romeo; Provvidenza Damiani; Attilio I Lo Monte; Luciano Lozio; Claudia Campanella; Antonella Marino Gammazza; Francesca Rappa; Giovanni Zummo; Massimo Cocchi; Everly Conway de Macario; Alberto J L Macario; Francesco Cappello
Journal:  Med Microbiol Immunol       Date:  2013-07-18       Impact factor: 3.402

Review 9.  Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view.

Authors:  Mi-Kyung Sung; Mi-Young Park
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

10.  Potential role of Lactobacillus plantarum in colitis induced by dextran sulfate sodium through altering gut microbiota and host metabolism in murine model.

Authors:  Sujuan Ding; Wenxin Yan; Jun Fang; Hongmei Jiang; Gang Liu
Journal:  Sci China Life Sci       Date:  2021-02-10       Impact factor: 6.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.